Keyhole-Limpet Hemocyanin

Phase 3Small molecule

Bristol-Myers Squibb

Keyhole-Limpet Hemocyanin is one of 339 small molecule programs targeting Kidney Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

338

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney CancerActive, not recruiting

LymphomaActive, not recruiting

Metastatic MelanomaActive, not recruiting

Chronic HepatitisActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Bladder CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Kidney CancerPhase 2

Active, not recruiting

LymphomaPhase 3

Active, not recruiting

Metastatic MelanomaPhase 1

Active, not recruiting

Chronic HepatitisPreclinical

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Bladder CancerPhase 3

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Small Cell Lung CancerPhase 2

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Phase 3

1 2

Trodelvy

Gilead

Preclinical

37 3

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 4

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 5

Spravato

WWim Janssens

Preclinical

2 6

Chirocaine

PPurdue Pharma LP

Preclinical

1 7

Nubain

AAultman Health Foundation

Preclinical

1 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Vfend

PPrism Pharmaceuticals

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoma4 trials

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT00004198

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT00004197

Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma

Terminated·UUniversity of Nebraska·Phase 2·NCT00006478·19 enrolled

Show 1 more trial

Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma

Unknown status·GGenitope Corporation·Phase 3·NCT00017290

Treatment1 trial

Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Unknown status·AAgouron Pharmaceuticals·Phase 4·NCT00005000·200 enrolled

Prostate Cancer1 trial

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003819·21 enrolled

Bladder Cancer1 trial

Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer

Completed·IIntracel·Phase 3·NCT00006034

Small Cell Lung Cancer1 trial

Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00004249

12 more indications

Breast Cancer1 trial

Vaccine Therapy in Treating Women With Metastatic Breast Cancer

Completed·OOncothyreon Canada Inc.·Phase 3·NCT00003638·950 enrolled

Immune Response1 trial

KLH Challenge to Explore the Human Immune Response

Unknown status·UUniversity of Oxford·N/A·NCT05876195·39 enrolled

Kidney Cancer1 trial

Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer

Unknown status·SSt. Luke's Medical Center·Phase 2·NCT00093522·28 enrolled

Adult Subject1 trial

Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects

Completed· Sanofi logo

Sanofi·Phase 1·NCT05845996·56 enrolled

Multiple Myeloma1 trial

Vaccine Therapy in Treating Patients With Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019097

Stem Cell Transplant1 trial

CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00369291·19 enrolled

Chronic Hepatitis1 trial

Keyhole Limpet Hemocyanin in Chronic Hepatitis C

Completed·MMedical University of Graz·N/A·NCT01509391·14 enrolled

Immunogenicity1 trial

Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00026624

Rheumatoid Arthritis1 trial

A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate

Completed· Roche logo

Roche·Phase 2·NCT00282308·103 enrolled

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02079480·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 20 trial records for Keyhole-Limpet Hemocyanin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Keyhole-Limpet Hemocyanin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Keyhole-Limpet Hemocyanin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Keyhole-Limpet Hemocyanin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoma4 trials

Treatment1 trial

Prostate Cancer1 trial

Bladder Cancer1 trial

Small Cell Lung Cancer1 trial

Breast Cancer1 trial

Immune Response1 trial

Kidney Cancer1 trial

Adult Subject1 trial

Multiple Myeloma1 trial

Stem Cell Transplant1 trial

Chronic Hepatitis1 trial

Immunogenicity1 trial

Rheumatoid Arthritis1 trial

Metastatic Melanoma1 trial

Growth1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News